Scientists at Georgetown University Medical Center have illuminated a previously underestimated factor contributing to temporal lobe epilepsy (TLE), a debilitating neurological disorder characterized by recurrent seizures and often profound memory impairment. Their groundbreaking research, published in the esteemed journal Annals of Neurology and supported by the National Institutes of Health (NIH), reveals a significant correlation between TLE and the premature aging of specific brain support cells, known as glial cells. By selectively targeting and eliminating these senescent cells in laboratory mice, the research team observed a remarkable reduction in seizure frequency, a notable improvement in memory recall, and even a protective effect against the development of epilepsy in a subset of the animal subjects. These promising findings were achieved through sophisticated genetic manipulation and the application of pharmacologically active compounds.
The significance of this research is particularly profound given the challenges in managing drug-resistant epilepsy. As explained by senior author Patrick A. Forcelli, Ph.D., a distinguished professor and chair of Georgetown School of Medicine’s Department of Pharmacology & Physiology, and the Jerome H. Fleisch & Marlene L. Cohen Endowed Professor of Pharmacology, a substantial portion of individuals diagnosed with epilepsy remain refractory to current pharmacological interventions. "A third of individuals living with epilepsy don’t achieve freedom from seizures with current medications," Dr. Forcelli stated, underscoring the urgent need for innovative therapeutic strategies. "Our hope is that senotherapy, which involves using medications to remove senescent, or aging cells, could potentially minimize the need for surgery and/or improve outcomes after surgery." This approach, known as senotherapy, offers a potential paradigm shift, moving beyond symptom management to addressing an underlying cellular mechanism contributing to the disease.
Temporal lobe epilepsy can stem from a diverse array of etiologies, ranging from traumatic brain injuries and cerebrovascular accidents like strokes to infectious agents such as meningitis, the presence of brain tumors, anomalies in vascular structures, and inherited genetic predispositions. Among the various forms of epilepsy, TLE stands out as the most prevalent type that exhibits a limited responsiveness to conventional medications, impacting approximately 40% of the global epilepsy population. This inherent resistance to standard treatments amplifies the importance of exploring alternative pathways for therapeutic intervention.
The genesis of this research involved a detailed examination of donated human brain tissue, specifically samples surgically excised from the temporal lobes of patients diagnosed with epilepsy. A striking observation emerged when these samples were compared to post-mortem brain tissue from individuals who had not experienced epilepsy; the epileptic tissue displayed a fivefold increase in the presence of senescent glial cells. Glial cells, while not directly involved in generating electrical impulses like neurons, play a critical role in supporting, protecting, and nourishing neuronal networks within the brain. Their dysregulation and premature aging could therefore have far-reaching consequences for neural function.
Building upon these compelling observations in human brain tissue, the research team proceeded to investigate the presence of similar cellular aging phenomena in a carefully constructed mouse model designed to recapitulate the key pathological features of TLE. Their investigation confirmed a distinct accumulation of aging markers at both the genetic and protein levels within the glial cells of these mice, evident within a mere two weeks following the experimental induction of brain injury that initiated the epileptic condition. This temporal correlation further strengthens the hypothesis that cellular senescence is an active contributor to the disease process.
The therapeutic interventions implemented to clear these senescent cells yielded profoundly encouraging outcomes. The senescent cell population was reduced by approximately half, leading to a cascade of beneficial effects in the treated mice. These animals demonstrated significantly fewer seizures, a marked improvement in their performance on maze-based memory assessments, and remarkably, a substantial proportion – about one-third of the cohort – were completely safeguarded from developing epilepsy altogether. This dual benefit of seizure control and cognitive enhancement suggests that targeting cellular aging could offer a comprehensive approach to mitigating the multifaceted impacts of TLE.
The pharmacological agents employed in the mouse studies represent a judicious selection of repurposed drugs with established safety profiles. The treatment regimen combined dasatinib, a targeted therapy currently utilized in the management of leukemia, with quercetin, a naturally occurring plant flavonoid found abundantly in fruits, vegetables, tea, and wine. Quercetin is recognized for its potent antioxidant and anti-inflammatory properties. This particular drug combination has garnered considerable attention in preclinical research for its efficacy in eliminating senescent cells across a spectrum of disease models.
The rationale for selecting dasatinib and quercetin extends beyond their senolytic capabilities; both drugs are presently undergoing evaluation in early-stage clinical trials for unrelated medical conditions. Dr. Forcelli highlighted a crucial advantage of dasatinib: its existing FDA approval for a form of leukemia. This regulatory status provides a well-documented safety profile, a critical factor that could significantly expedite the transition from preclinical studies to human clinical trials for epilepsy. The potential for repurposing existing, safe drugs offers a streamlined and cost-effective pathway to developing new therapies.
The implications of these findings extend far beyond temporal lobe epilepsy, hinting at broader applications in understanding and treating conditions associated with brain aging and neurodegeneration. Tahiyana Khan, Ph.D., and David J. McFall, the study’s first co-authors and trainees in Dr. Forcelli’s laboratory, pointed to recent research linking glial cell aging to both the natural aging process of the brain and neurodegenerative disorders such as Alzheimer’s disease. This burgeoning connection forms a significant focus of their ongoing investigations.
"We have ongoing studies using other repurposed drugs that can impact senescence as well as studies in other rodent models of epilepsy," Dr. Forcelli elaborated. "We would like to understand the critical windows for intervention in epilepsy, and the hope is that these studies will lead to clinically useful treatments." This forward-looking perspective underscores the research team’s commitment to translating these promising preclinical results into tangible therapeutic benefits for patients. Future research will likely explore the optimal timing and duration of senolytic interventions, as well as investigate their efficacy in conjunction with or as alternatives to existing epilepsy treatments. The pursuit of understanding the intricate interplay between cellular aging and neurological disorders promises to unlock new avenues for therapeutic development, offering hope for improved outcomes in a wide range of age-related brain conditions.
The research team involved in this pivotal study at Georgetown University includes Abbas I. Hussain, Logan A. Frayser, Timothy P. Casilli, Meaghan C. Steck, Irene Sanchez-Brualla, Ph.D., Noah M. Kuehn, Michelle Cho, Jacqueline A. Barnes, M.D., Brent T. Harris, M.D., Ph.D., and Stefano Vicini, Ph.D., in addition to Dr. Forcelli, Ms. Khan, and Mr. McFall. The authors have declared no personal financial conflicts of interest pertinent to the findings of this study. This work was generously supported by grants from the National Institutes of Health, including R21NS125552, F99NS129108, T32NS041218, T32GM142520, F30NS143374-01, T32GM144880, and T3GM142520. Dr. Forcelli also benefits from support through his endowed professorship.
About the Author
